Bopindolol (INN) is a beta blocker. It is an ester which acts as a prodrug for "pindolol":http://drugbank.ca/drugs/DB00960.
Indication
For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.
Pharmacology
Bopindolol is a prodrug of pindolol. Pindolol is a non-selective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. Pindolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Pindolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Pindolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, pindolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.
Bopindolol is an ester prodrug of Pindolol (P468000). Bopindolol is a long acting β-adrenoceptor blocking agent. Bopindolol displays antispasmogenic activity mediated by α1-adrenoceptors and 5-HT2 receptors.
A methylindole that is 2-methyl-1H-indol-4-ol in which the hydrogen of the hydroxy group is replaced by a 2-(benzoyloxy)-3-(tert-butylamino)propyl group.
References
PubChem Literature
From Data Sources
• Brodde, O.E. et al.: J. Cardio. Pharmacol., 8, S70 91986); Doggrell, S.A.: Med, Sci. Res., 17, 681 (1984)
• Turner, D.R. et al.: Br. J. Clin. Pharmacol., 17, 295 (1984)